Outlook Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 2, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Market Cap	102	57	128	58	277	383
Market Cap Growth	81.32%	-55.25%	121.94%	-79.26%	-27.58%	318.17%
Enterprise Value	120.81	49.23	112.98	34.12	259.93	379.37
Last Close Price	0.84	1.06	5.34	4.42	24.40	43.40
PS Ratio	304.28	40.41	-	-	-	-
PB Ratio	-	-1.77	-1.75	-3.98	31.74	83.11
P/TBV Ratio	-1.64	-1.15	-1.35	-3.83	29.62	71.91
EV/Sales Ratio	362.63	34.82	-	-	-	-
Debt / Equity Ratio	-0.39	-0.01	0.00	0	0.00	2.37
Net Debt / Equity Ratio	-0.67	-0.69	-0.20	-0.84	-0.74	-0.56
Net Debt / EBITDA Ratio	-0.32	-0.33	-0.21	-0.23	0.10	0.05
Net Debt / FCF Ratio	-0.41	-0.43	-0.21	-0.28	0.11	0.05
Asset Turnover	0.02	0.06	0	0	0	0
Inventory Turnover	0.45	0.81	-	-	-	-
Quick Ratio	0.27	0.21	0.35	0.50	0.88	2.14
Current Ratio	0.54	0.38	0.64	0.66	1.39	3.19
Return on Equity (ROE)	180.49%	118.61%	172.24%	2069.13%	-989.99%	-1430.33%
Return on Assets (ROA)	-289.99%	-276.05%	-234.63%	-174.69%	-245.71%	-243.18%
Return on Invested Capital (ROIC)	1002.68%	2924.59%	9990.52%	-122626.00%	-2569.00%	4584.32%
Return on Capital Employed (ROCE)	253.40%	327.44%	509.22%	1886.06%	-507.46%	-519.79%
Buyback Yield / Dilution	-121.62%	-87.59%	-48.29%	-17.96%	-38.91%	-110.43%
Total Shareholder Return	-121.62%	-87.59%	-48.29%	-17.96%	-38.91%	-110.43%

SEC Filings: 10-K · 10-Q